Today's Research Reports on GeneNews Limited, Centric Health Corporation, Resverlogix Corp. and TSO3 Inc.
NEW YORK, NY / ACCESSWIRE / July 26, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
GeneNews Limited
https://ub.rdinvesting.com/news/?ticker=GEN-TO
Centric Health Corporation
https://ub.rdinvesting.com/news/?ticker=CHH-TO
Resverlogix Corp.
https://ub.rdinvesting.com/news/?ticker=RVX-TO
TSO3 Inc.
https://ub.rdinvesting.com/news/?ticker=TOS-TO
GeneNews Limited's stock jumped 7.14% Tuesday, to close the day at $0.15. The stock recorded a trading volume of 240,500 shares, which was below its three months average volume of 498,532 shares. In the last year, GeneNews Limited's shares have traded in a range of 0.12 - 0.57. The share price has gained 20.00% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.17 is below its 200-day moving average of $0.29. Shares of GeneNews Limited have fallen approximately 51.61 percent year-to-date.
Access RDI's GeneNews Limited Research Report at:
https://ub.rdinvesting.com/news/?ticker=GEN-TO
On Tuesday, shares in Centric Health Corporation recorded a trading volume of 21,750 shares, which was below the three months average volume of 271,806 shares. The stock ended the day flat at 0.69. The share price has gained 245.00% from its 52 week low with a 52 week trading range of 0.20 - 0.91.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.69 is below its 200-day moving average of $0.73. Shares of Centric Health Corporation have gained approximately 16.95 percent year-to-date.
Access RDI's Centric Health Corporation Research Report at:
https://ub.rdinvesting.com/news/?ticker=CHH-TO
Resverlogix Corp.'s stock jumped 9.09% Tuesday, to close the day at $1.56. The stock recorded a trading volume of 204,066 shares, which was above its three months average volume of 70,219 shares. In the last year, Resverlogix Corp.'s shares have traded in a range of 1.12 - 2.47. The share price has gained 39.29% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $1.45 is below its 200-day moving average of $1.89. Shares of Resverlogix Corp. have fallen approximately 8.24 percent year-to-date.
Access RDI's Resverlogix Corp. Research Report at:
https://ub.rdinvesting.com/news/?ticker=RVX-TO
On Tuesday, shares in TSO3 Inc. recorded a trading volume of 343,162 shares, which was above the three months average volume of 134,897 shares. The stock ended the day 2.20% higher at 3.25. The share price has gained 47.73% from its 52 week low with a 52 week trading range of 2.20 - 3.82.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $3.02 is below its 200-day moving average of $3.04. Shares of TSO3 Inc. have gained approximately 14.84 percent year-to-date.
Access RDI's TSO3 Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=TOS-TO
Our Actionable Research on GeneNews Limited (TSX: GEN.TO), Centric Health Corporation (TSX: CHH.TO), Resverlogix Corp. (TSX: RVX.TO) and TSO3 Inc. (TSX: TOS.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer or a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
